Drexel University College of Medicine

Clinical trials for iQ-007, a first-in-class small molecule modulator of EAAT2, are set to begin next year. This molecule, developed for drug-resistant epilepsy, could also treat various neurological, neurodegenerative, and psychiatric conditions. The development involved global collaboration, including institutions like Harvard Medical School, and was commercialized by iQure Pharma.

Tularemia, caused by Francisella tularensis, is a rare zoonotic disease and potential bioweapon, transmitted via insect bites, animal contact, or inhalation. It's more common in men due to occupational exposure. Symptoms vary by infection route, including fever, ulcers, and lymphadenopathy. Diagnosis is challenging; treatment involves aminoglycosides or fluoroquinolones. Prevention includes avoiding insect bites and handling animals carefully.